Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-Current DebtShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Non-Current Debt: 2021-2025

Historic Non-Current Debt for Ascendis Pharma A (ASND) over the last 1 years, with Sep 2025 value amounting to $2.0 billion.

  • Ascendis Pharma A's Non-Current Debt rose 62.60% to $390.1 million in Q4 2024 from the same period last year, while for Dec 2024 it was $390.1 million, marking a year-over-year increase of 62.60%. This contributed to the annual value of $395.1 million for FY2024, which is 64.69% up from last year.
  • Latest data reveals that Ascendis Pharma A reported Non-Current Debt of $390.1 million as of Q4 2024, which was up 62.60% from $239.9 million recorded in Q4 2023.
  • In the past 5 years, Ascendis Pharma A's Non-Current Debt ranged from a high of $395.4 million in Q4 2022 and a low of $112.1 million during Q4 2021.
  • For the 3-year period, Ascendis Pharma A's Non-Current Debt averaged around $341.8 million, with its median value being $390.1 million (2024).
  • Its Non-Current Debt has fluctuated over the past 5 years, first skyrocketed by 252.82% in 2022, then plummeted by 39.32% in 2023.
  • Ascendis Pharma A's Non-Current Debt (Quarterly) stood at $112.1 million in 2021, then skyrocketed by 252.82% to $395.4 million in 2022, then slumped by 39.32% to $239.9 million in 2023, then skyrocketed by 62.60% to $390.1 million in 2024.
  • Its Non-Current Debt stands at $390.1 million for Q4 2024, versus $239.9 million for Q4 2023 and $395.4 million for Q4 2022.